Skip to main content

Table 1 Baseline demographic and clinical characteristics stratified by 12 week and 24 week duration (n = 93)

From: Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

Characteristic, n (%)

Overall (n = 93)

12 week (n = 61)

24 week (n = 26)

Age, median (25%, 75%)

41 (35–49)

41 (34–49)

40 (35–48)

Male sex, n (%)

77 (83)

49 (80)

23 (88)

Drug use in the last 6 months (injecting/non-injecting)

77 (83)

48 (79)

25 (96)

Injecting drug use in the last month

55 (59)

39 (64)

15 (58)

 Heroin

33 (35)

23 (37)

10 (38)

 Cocaine

10 (11)

7 (11)

3 (12)

 Amphetamines

14 (15)

7 (11)

6 (23)

 Other opiates

11 (12)

8 (13)

3 (12)

 Benzodiazapines

2 (2)

2 (3)

0 (0)

Injecting drug use frequency in the last month

 Never

38 (41)

22 (36)

11 (42)

  < daily

40 (43)

29 (48)

10 (38)

  > daily

15 (16)

10 (16)

5 (19)

Opioid substitution treatment (ever)

82 (88)

56 (92)

21 (81)

OST and recent injecting (past month) at enrolment

 No OST, recent injecting

30 (32)

20 (33)

9 (33)

 OST, no recent injecting

23 (25)

15 (25)

5 (19)

 OST, recent injecting

40 (43)

26 (43)

12 (44)

OST and recent injecting (past month) at baseline

 No OST, recent injecting

21 (23)

14 (23)

6 (23)

 OST, no recent injecting

34 (37)

21 (34)

8 (31)

 OST, recent injecting

38 (41)

26 (43)

12 (46)

Stage of liver disease

 No or mild fibrosis (F0-F1)

63 (68)

44 (72)

16 (62)

 Moderate or advanced fibrosis (F2-F3)

20 (22)

12 (20)

5 (19)

 Cirrhosis (F4)

10 (11)

5 (8)

5 (19)

Study site distribution

 Europe

38 (41)

24 (39)

13 (50)

 Australia

40 (43)

27 (44)

9 (35)

 Canada

15 (16)

10 (16)

4 (15)